Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University Health Network, Toronto |
---|---|
Information provided by: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT00188201 |
The estimated global prevalence of hepatitis C (HCV) infection is approximately 3% (170 million individuals). In Canada there are an estimated 240,000 people infected with HCV. The current study addresses the hypothesis that neurocognitive and neurochemical abnormalities may occur in individuals with HCV-infection who do not have liver cirrhosis or vasculitic neuropathy, and this may result from a direct effect of HCV on the Central Nervous System (CNS). The purpose of this study is to assess whether infection with the Hepatitis-C virus is associated with changes in thinking skills and brain chemistry, in patients who do not have liver cirrhosis. In addition, we are examining whether such changes in thinking skills and brain chemistry are reversed by antiviral treatment. We are also studying whether factors such as fatigue and depression have an effect on thinking skills in people with Hepatitis-C. In order to take into account the impact of having viral hepatitis, we will be comparing the results of the Hepatitis-C group to the results of a group of patients with Hepatitis-B, and to a group of individuals who do not have Hepatitis.
Condition |
---|
Hepatitis C Hepatitis B |
Study Type: | Observational |
Study Design: | Longitudinal, Defined Population, Prospective Study |
Official Title: | An Investigation of Cognitive Functioning and Brain Metabolites in Patients With Non-Cirrhotic Hepatitis-C Both Pre- and Post-Treatment With Antiviral Medication |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Additional Inclusion Criteria For HCV and HBV patients:
Exclusion Criteria:
presence of any of the following medical conditions:
Contact: Mirela Mrkonjic | 416-603-5800 ext 3217 |
Canada, Ontario | |
Liver Clinic, Toronto Western Hospital, UHN. | Recruiting |
Toronto, Ontario, Canada, M5T 2S8 | |
Contact: E.J.L. (Jenny) Heathcote, MD 416-603-5914 | |
Principal Investigator: E.J.L (Jenny) Heathcote, M.D. |
Principal Investigator: | E.J.L (Jenny) Heathcote, MD | UHN - Toronto Western Hospital, University of Toronto |
Study ID Numbers: | 01-0827-E, EOP-48307 |
Study First Received: | September 9, 2005 |
Last Updated: | November 28, 2005 |
ClinicalTrials.gov Identifier: | NCT00188201 History of Changes |
Health Authority: | Canada: Health Canada |
Hepatitis C neucognitive functions neuropsychological testing antiviral treatment |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Hepatitis B |
Hepatitis, Viral, Human DNA Virus Infections Hepatitis C Antiviral Agents |
Anti-Infective Agents Liver Diseases RNA Virus Infections Flaviviridae Infections Hepatitis, Viral, Human Hepadnaviridae Infections Antiviral Agents Pharmacologic Actions |
Hepatitis Virus Diseases Digestive System Diseases Therapeutic Uses Hepatitis B DNA Virus Infections Hepatitis C |